Compare RBA & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBA | GMAB |
|---|---|---|
| Founded | 1958 | 1999 |
| Country | United States | Denmark |
| Employees | 7900 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8B | 19.1B |
| IPO Year | N/A | N/A |
| Metric | RBA | GMAB |
|---|---|---|
| Price | $99.95 | $29.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $128.75 | $41.08 |
| AVG Volume (30 Days) | ★ 1.7M | 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.52 | $15.54 |
| Revenue Next Year | $3.94 | $14.29 |
| P/E Ratio | $52.68 | ★ $1.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $87.87 | $17.24 |
| 52 Week High | $119.58 | $35.43 |
| Indicator | RBA | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 38.57 | 40.25 |
| Support Level | $97.48 | $28.17 |
| Resistance Level | $106.54 | $33.75 |
| Average True Range (ATR) | 4.74 | 0.75 |
| MACD | -0.98 | 0.01 |
| Stochastic Oscillator | 16.15 | 44.78 |
RB Global has evolved into a leading global marketplace that connects buyers and sellers of commercial assets and vehicles. It is the result of the 2023 combination of Ritchie Bros. and IAA. Ritchie Bros.' roots were as an auctioneer facilitating transactions of commercial, construction, and transportation equipment (excavators, bulldozers, forklifts, and commercial trucks and trailers). However, it has evolved into an omnichannel marketplace. IAA has similar roots, though primarily focused on the salvage auction segment for consumer automobiles. The group provides ancillary services including title processing, transportation/towing, financing, data and appraisal, and so on. Its activities are international, though skewing approximately two-thirds to North America.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.